Core Viewpoint - The company, Zhejiang Wande Kai Fluid Equipment Technology Co., Ltd., is experiencing a mixed performance with a significant portion of its revenue coming from overseas, benefiting from the depreciation of the RMB [2][3]. Company Overview - Zhejiang Wande Kai is located in Donggang Village, Longxi Town, Yuhuan City, Zhejiang Province, and was established on October 31, 2016, with its listing date on September 19, 2022 [7]. - The company's main business includes the design, development, production, and sales of plumbing equipment, valves, pipe fittings, and smart home products [2][7]. - The revenue composition is as follows: valves account for 57.70%, pipe fittings for 40.79%, and other products for 1.51% [7]. Financial Performance - For the period from January to September 2025, the company achieved an operating income of 616 million yuan, a year-on-year decrease of 16.85%, and a net profit attributable to shareholders of 83.59 million yuan, down 27.80% year-on-year [7]. - The company has distributed a total of 120 million yuan in dividends since its A-share listing [8]. Market Position and Recognition - The company has been recognized as a "Little Giant" enterprise by the Ministry of Industry and Information Technology, indicating its strong innovation capabilities and market share in niche markets [2]. - As of the 2024 annual report, overseas revenue accounted for 82.39% of total revenue, benefiting from the depreciation of the RMB [3]. Stock Performance - On February 6, the stock price of Wande Kai increased by 0.68%, with a trading volume of 30.98 million yuan and a turnover rate of 3.92%, resulting in a total market capitalization of 3.108 billion yuan [1]. - The average trading cost of the stock is 29.73 yuan, with the current price near a support level of 30.87 yuan [6].

Core Viewpoint - Wuzhou Medical has shown a slight increase in stock price and is benefiting from the depreciation of the RMB, with a significant portion of its revenue coming from overseas sales [1][3]. Group 1: Company Overview - Wuzhou Medical specializes in the research, production, and sales of disposable sterile infusion medical devices, including various types of syringes, infusion sets, and other medical supplies [2]. - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, indicating its strong market position and innovation capabilities [2]. - As of January 20, the company reported a revenue of 345 million yuan for the first nine months of 2025, reflecting a year-on-year growth of 0.82%, while net profit decreased by 46.09% to approximately 18.51 million yuan [7]. Group 2: Financial Performance - The company's overseas revenue accounts for 96.88% of total revenue, benefiting from the depreciation of the RMB [3]. - The average trading cost of the stock is 42.76 yuan, with the current price near a support level of 41.29 yuan, indicating potential volatility [6]. - The company has distributed a total of 81.6 million yuan in dividends since its A-share listing [8]. Group 3: Market Position and Shareholder Information - Wuzhou Medical operates under the pharmaceutical and medical device industry, focusing on medical consumables [7]. - As of September 30, 2025, the company saw a decrease in the number of shareholders by 2.28%, with an increase in average circulating shares per person by 2.33% [7][9].

Core Viewpoint - The company, Hangzhou Hemai Electric Power Electronics Co., Ltd., is experiencing positive market movements due to its involvement in the photovoltaic and energy storage sectors, benefiting from the depreciation of the RMB and plans for share buybacks and increases in holdings by major shareholders [2][3]. Group 1: Company Overview - Hangzhou Hemai Electric Power Electronics Co., Ltd. specializes in the research, development, manufacturing, and sales of photovoltaic inverters, energy storage products, and electrical equipment [2][3]. - The company's main products include micro-inverters, monitoring devices, distributed photovoltaic power generation systems, modular inverters, and energy storage systems [2][3]. - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, indicating its strong market position and technological capabilities [2]. Group 2: Financial Performance - As of the end of September, the company reported a revenue of 1.323 billion yuan for the first nine months of 2025, representing a year-on-year growth of 4.57% [8]. - The net profit attributable to the parent company was -59.1154 million yuan, a decrease of 124.07% year-on-year [8]. - The company has distributed a total of 1.306 billion yuan in dividends since its A-share listing, with 1.186 billion yuan distributed over the past three years [8]. Group 3: Market Activity - On February 6, the company's stock price increased by 0.62%, with a trading volume of 161 million yuan and a turnover rate of 1.19%, bringing the total market capitalization to 13.538 billion yuan [1]. - The company has a significant overseas revenue share of 64.25%, benefiting from the depreciation of the RMB [3]. - Hangzhou Kaikai Holdings Group plans to increase its stake in Hemai, with an investment of no less than 111.5 million yuan and up to 223 million yuan, supported by a special loan from China CITIC Bank [3].

Core Viewpoint - The company, Zhejiang Kaichuang Electric Co., Ltd., has shown growth potential through its focus on specialized and innovative electric tools, benefiting from the depreciation of the RMB and expanding its e-commerce operations. Group 1: Company Overview - Zhejiang Kaichuang Electric Co., Ltd. was established on December 28, 2015, and went public on June 19, 2023. The company specializes in the research, design, production, and sales of handheld electric tools and core components, with 99.46% of its revenue coming from electric tools [6]. - The company has been recognized as a "specialized and innovative" small giant enterprise by the Ministry of Industry and Information Technology, indicating its strong market position and innovation capabilities [2]. Group 2: Financial Performance - As of January 30, the company reported a total revenue of 490 million yuan for the period from January to September 2025, reflecting a year-on-year decrease of 12.96%. The net profit attributable to the parent company was -10.46 million yuan, a decline of 119.10% year-on-year [6]. - The company has distributed a total of 67.12 million yuan in dividends since its A-share listing [7]. Group 3: Market Position and Trends - The company has developed 20 new lithium battery products in 2023, gaining recognition from clients such as Bosch and Harbor Freight Tools. Currently, sales from lithium battery products account for less than 10% of total revenue, indicating significant growth potential [2]. - The company's overseas revenue accounted for 91.85% of total revenue, benefiting from the depreciation of the RMB [2]. Group 4: E-commerce Development - Since 2018, the company has been expanding its e-commerce business, establishing cross-border e-commerce companies in Jinhua, Hangzhou, and Shenzhen. It promotes and sells its self-branded electric tools through platforms like Amazon. In 2024, online sales revenue increased by 58.64% year-on-year [2].

Core Viewpoint - Guangdian Measurement experienced a stock price decline of 2.07% on February 6, 2023, with a current price of 23.70 CNY per share and a market capitalization of 13.82 billion CNY [1] Financial Performance - For the period from January to September 2025, Guangdian Measurement achieved a revenue of 2.416 billion CNY, representing a year-on-year growth of 11.86% [2] - The net profit attributable to shareholders for the same period was 239 million CNY, reflecting a year-on-year increase of 26.51% [2] Shareholder Information - As of September 30, 2025, the number of shareholders for Guangdian Measurement was 29,200, a decrease of 0.72% from the previous period [2] - The average number of circulating shares per shareholder increased by 2.76% to 18,508 shares [2] Dividend Distribution - Guangdian Measurement has distributed a total of 607 million CNY in dividends since its A-share listing, with 481 million CNY distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder, holding 9.6675 million shares, a decrease of 3.6515 million shares from the previous period [3] - New institutional shareholders include Guangfa Multi-Factor Mixed Fund and Guangfa Balanced Growth Mixed A, holding 8.4365 million shares and 2.9583 million shares respectively [3]

来源：大象新闻 本文来自微信公众号"大象新闻" 嘉晨智能招股说明书（上会稿）显示，公司本次拟公开发行人民币普通股1800万股，采用超额配售选择 权发行的股票数量不超过270万股。合计发行的股票数量不超过2070万股（含本数）。根据招股书，嘉 晨智能拟募集资金2.6亿元，用于电气控制系统生产基地建设项目、研发中心建设项目。 嘉晨智能位于郑州市，主要产品包括电机驱动控制系统、整机控制系统和车联网产品及应用等，目前下 游主要应用场景为工业车辆，并已逐步拓展至挖掘机械、高空作业机械等其他工程机械场景以及场地 车、移动机器人等多元化应用领域，客户包括杭叉集团、安徽合力、诺力股份、龙工、柳工、比亚迪、 徐工、凯傲、海斯特国内外主要工业车辆整车制造厂商。 2025年6月，嘉晨智能向北交所递交招股书，并获受理。 公司被认定为国家级专精特新"小巨人"企业、河南省第一批重点"小巨人"企业、国家高新技术企业、 2022年度国家知识产权优势企业、工信部"2021年绿色制造名单"企业、河南省"瞪羚"企业等。 据大河财立方消息，2月5日晚间，北交所上市委员会公告，定于2026年2月12日上午9时召开2026年第15 次审议会议，审议河南 ...

部分传统产业企业有望成为"小巨人" 今年1月，工业和信息化部发布新版《优质中小企业梯度培育管理办法》（以下简称《办法》），对专 精特新中小企业认定标准、"小巨人"企业认定标准进行了完善。 活动现场，广东省工信厅、广东省发改委、广东省科技厅评审专家曾国富以"政策解读+案例分析"的形 式，对重点"小巨人"、专精特新"小巨人"企业申报要点展开解读。 《办法》中，专精特新"小巨人"企业认定标准有较大的变化，企业主导产品的范围有所拓展。属于改造 提升传统产业、培育壮大新兴产业、布局建设未来产业，位于产业链关键环节，对提升产业链供应链韧 性和安全水平发挥重要作用的产品均可纳入。曾国富指出，这一变化将使部分传统产业企业，如矿业、 冶金、化工、轻工、纺织、机械、船舶、建筑等产业领域企业认定专精特新"小巨人"成为可能。 2月4日，广州市工业和信息化局举办全市重点专精特新"小巨人"政策宣贯活动。南都N视频记者从活动 中获悉，截至2025年底，广州市全市累计培育专精特新"小巨人"企业482家、重点"小巨人"企业74家、 专精特新中小企业7175家，专精特新企业年度营业总收入超过8000亿元，成为本市发展新质生产力的重 要力量。 曾 ...

日前，漳州市九龙江闽台润信石化产业基金公开遴选第一批子基金管理机构：为深入贯彻福建省漳 州市《千百亿产业培育行动加护》决策部署，按照市属国企设立基金支持漳州市产业集群工作方 案, 漳州市九龙江闽台润信石化产业基金（以下简称"九龙江母基金"）拟联合社会资本组建设立子 基金，现公开遴选基金管理机构，有关事项公告如下： 公告指出：九龙江母基金立足福建漳州，放眼全国，主要投向漳州市"9+5"产业集群产业领域及 国家战略新兴产业领域项目，重点支持福建省"专精特新"企业，关注漳州市产业招引集聚。具体 行业上，九龙江母基金重点关注新一代信息技术、智能制造、绿色石化与新材料、医疗健康先进产 业群，新一代信息技术重点关注集成电路半导体、数字经济、人工智能领域(包括软件和硬件);智 能制造重点布局新能源汽车及零部件、机器人与数控机床、航空航天领域、新能源及装备领域;绿 色石化与新材料重点关注高端新材料、关键基础性及战略性材料、精细化工领域；医疗健康先关注 医疗器械、生物医药、生物制造及中医药领域等。 据悉，科创子基金定位为九龙江母基金出资设立。科创子基金主要投向新一代信息技术、智能制 造、绿色石化与新材料、医疗健康先进产业群及国 ...

史合群：乘限抗 与低蛋白日粮政 策东风，广州饲 料行业坚定专精 特新道路┃穗风 不惑_南方+_南 方plus 编者按：四十年 栉风沐雨，羊城 饲界潮涌珠江。 改革开放以来， 广州饲料产业乘 势而上，谱写奋 进史诗。依托技 术创新，穗风动 物营养星火燎 原，从本土走向 世界。浪潮之 中，广州市饲料 行业协会激荡四 十年，成为行业 发展标杆。为总 结协会及广州饲 料行业发展成 果，洞察行业走 势，南方农村报 推出"穗风·不 惑"系列报道。 以协会为镜，观 行业之变；以广 州为窗，察饲界 之势。敬请垂 注。 "乘限抗、低蛋 白日粮政策东 风，广州饲料行 业尤其是功能性 饲料添加剂产业 大有可为。"广 州市饲料行业协 会会长、科虎生 物总经理史合群 说。 作为广州市科虎 生物技术有限公 司（简称"科虎 生物"）总经 理，史合群带领 科虎生物在植物 源功能性饲料添 加剂领域闯出一 条"专精特新"之 路。2023年至 今，史合群接棒 任广州市饲料行 业协会会长，传 承协会团结、开 放、和谐、奉献 精神，服务行 业，推动行业向 专精特新、绿色 生态、可持续方 向发展。 广州市饲料行业协会会长、科虎生物总经理史合群 协会40 ...

在四川华都核设备制造有限公司，车间内机器轰鸣，生产线自动化程度高达95%。该公司深耕都江堰17 年，是国内仅有的3家持有民用核安全设备制造许可证的企业之一，更是成都专精特新培育方向下的典 型代表，这家国家级专精特新"小巨人"企业，多年来聚焦核电关键技术攻坚。 "自2014年以来，我们持续享受高新技术企业15%的企业所得税优惠税率，叠加研发费用加计扣除政 策，截至目前累计享受税费优惠超1亿元。"该公司相关负责人介绍，稳定的资金支持让企业敢于加码研 发，不仅组建起70余人的专业研发团队，每年预提不低于上年销售收入7%的资金用于技术突破，还投 入超过2000万元升级智能产线，使整体生产效率提升超30%。 税费优惠政策对于企业突破核心技术、扩大生产规模有着重要意义。2月5日，红星新闻记者从成都市税 务局了解到，为持续助力企业突破发展瓶颈、攻坚核心技术，成都税务部门紧扣政策导向，2025年落实 科技创新与制造业发展主要政策减免税费超445亿元，其中支持科技投入和成果转让减免超154亿元，支 持制造业高质量发展减免超167亿元，以税费红利为企业创新赋能。 ▲图据图虫创意 作为国家首批重点支持的专精特新"小巨人"企业，四川 ...